[
    [
        {
            "time": "2018-04-01",
            "original_text": "医药行业重点公司2018年一季报业绩前瞻：聚焦一季报 关注创新+升级主线",
            "features": {
                "keywords": [
                    "医药行业",
                    "一季报",
                    "业绩前瞻",
                    "创新",
                    "升级"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药行业重点公司2018年一季报业绩前瞻：聚焦一季报 关注创新+升级主线",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-03-31",
            "original_text": "健帆生物(300529)年报点评：业绩增长步入快车道 适应症拓展空间广阔",
            "features": {
                "keywords": [
                    "健帆生物",
                    "年报",
                    "业绩增长",
                    "适应症",
                    "拓展空间"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物(300529)年报点评：业绩增长步入快车道 适应症拓展空间广阔",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-04-01",
            "original_text": "医药行业2018年4月份投资月报暨Q2季度策略：创新+升级 从初春到盛夏",
            "features": {
                "keywords": [
                    "医药行业",
                    "投资月报",
                    "Q2季度策略",
                    "创新",
                    "升级"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药行业2018年4月份投资月报暨Q2季度策略：创新+升级 从初春到盛夏",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        }
    ]
]